We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical and healthcare products manufacturing giant CAPS Holdings Limited will reopen its Zimbabwean penicillin plant at the end of August, the company announced.
Avicena Group has announced that a Phase II clinical trial of two combination therapies incorporating ALS-08, one of its proprietary drug candidates for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's Disease) has been initiated.
Abbott Pharmaceutical and AstraZeneca have been granted the U.S rights to use Irish drugmaker Elan's NanoCrystal technology to develop fixed-dose combination products.
Indian drugmaker SkyePharma has completed negotiations with Mundipharma International Holdings Limited through which it will reacquire the rights for the marketing and distribution of DepoBupivacaine in Europe and other international markets, excluding the U.S., Canada and Japan.
Technip has been awarded a contract by the Chengdu Institute of Biological Products (CDIBP) for the design, construction and qualification of a new production unit for Japanese encephalitis vaccines.
The Irish Pharmaceutical Union (IPU) are meeting the Minister for Health Mary Harney this week to contest the co-location of pharmacies with general practices in health centres, Irish Medical Times has learned.
The German company behind a disastrous drug trial that left six volunteers in intensive care declared itself bankrupt yesterday after being abandoned by frightened investors.
The venture capital arm of Danske Bank A/S is buying eastern European drug companies to create a major competitor in a region where drug stocks are rising faster than the region's benchmark index.
Shire plc announced the availability of DAYTRANA (methylphenidate transdermal system), the first and only transdermal medication approved to treat the symptoms of ADHD.
Provincial health ministers who will meet today to approve a progress report on a national pharmaceutical strategy say a pan-Canadian program to cover the burdensome costs of some drugs cannot fly without the financial help of the federal government.